AXT Inc vs ClearPoint Neuro Inc — how do they compare? AXT Inc trades at $79.03 (market cap $4.83B), while ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M). The key difference: AXT Inc is far larger — about 10.9× ClearPoint Neuro Inc's market cap, and AXT Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| AXTI | CLPT | |
|---|---|---|
Market Cap | $4.83B | $444.14M |
Sector | Technology | Health |
52-Week High | $140.83 | $29.60 |
52-Week Low | $2.05 | $8.66 |
Enterprise Value | $4.50B | $478.72M |
Signals from Pluang's Aura AI — not financial advice
AXTI trades at $88.58, up 17.84% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat. The stock is technically bullish with support at $82 and resistance at $92. Fundamentally, revenue grew to $126 million in 2026 with a net profit margin of 3.23%, though valuation ratios like P/E of 2,460.33 appear elevated. Recent news highlights surging indium phosphide demand driven by AI data centers.
Outlook is positive with analyst consensus at Buy (72.73%) and a $72.50 price target, but risks include high valuation, cash flow volatility, and dependence on AI-driven demand. The stock offers growth exposure to semiconductor substrates, yet investors should weigh profitability sustainability against rich multiples.
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
Trailing returns across standard periods
Latest headlines on both assets
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →